Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Amisulpride Orally Disintegrating Tablets in Healthy Chinese Subjects
NCT06066112Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Sep 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amisulpride in schizophrenia (2 cohorts), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 48 hours and 1 more. Status: unknown.
02
Drugs
amisulpride
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06066112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066112.